



NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034.
Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2017

(₹ in millions except per share data)

	Quarter ended			Year ended
	30 June 2017 (Unaudited) (Refer note 4)	31 Mar 2017 (Refer note 3)	30 June 2016 (Unaudited) (Refer note 4)	31 Mar 2017 (Audited)
Revenue				
Revenue from operations	4,453	5,778	3,403	20,650
Other income	34	(6)	52	139
Total revenues	4,487	5,772	3,455	20,789
Expenses				
Cost of materials consumed	1,286	1,010	1,308	5,208
Excise duty	172	131	151	448
Purchases of stock-in-trade	256	56	216	971
Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	(448)	106	(597)	(188)
Employee benefits expense	631	796	517	2,432
Finance costs	39	64	32	185
Depreciation and amortisation expense	150	135	131	544
Other expenses	1,189	1,268	1,036	4,945
Total expenses	3,275	3,566	2,794	14,545
Profit before tax	1,212	2,206	661	6,244
Tax expense				
Current tax	266	477	167	1,354
Deferred tax	9	(56)	0	1
Tax for earlier years	-	21	19	40
Profit after tax	937	1,764	475	4,849
Other comprehensive income (net of taxes)				
Items that will not be reclassified to profit or loss				
Re-measurement gains/(losses) on defined benefit plans	(8)	(27)	(8)	(50)
Net (loss)/gain on FVTOCI equity securities	7	19	2	28
Exchange differences on translation of foreign operations	38	2	-	(12)
Total comprehensive income	974	1,758	469	4,815
Profit attributable to:				
Owners of the parent	940	1,767	477	4,860
Non-controlling interests	(3)	(3)	(2)	(11)
Total comprehensive income attributable to:				
Owners of the parent	977	1,761	471	4,826
Non-controlling interests	(3)	(3)	(2)	(11)
Paid-up equity share capital of ₹2 each	349	349	348	349
Other equity				16,144
Earnings per share (non-annualised)				
Basic	5.59	10.10	2.74	27.78
Diluted	5.58	10.09	2.73	27.75



NATCO Pharma Limited

Notes to the consolidated results:

1. The Company adopted Indian Accounting Standard ("Ind AS") from 1 April 2016 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.
2. The consolidated financial results for the quarter ended 30 June 2017 have been reviewed by the Audit Committee of the board and approved by the Board of Directors of the Company at their meeting held on 7 August 2017.
3. The figures of the quarter ended 31 March 2017 are the balancing figures between audited figures in respect of full financial year ended 31 March 2017 and the unaudited published year to date figures upto 31 December 2016 which were subjected to limited review.
4. The results for the quarter ended 30 June 2017 and 30 June 2016 presented were subjected to a limited review by the statutory auditors of the Company.
5. The Company operates in one reportable segment which is "Pharmaceuticals".
6. The Board of Directors at their meeting held on 7 August 2017 have recommended an interim dividend of ₹1.25 per equity share of ₹2 each for the current financial year.

By Order of the Board

A handwritten signature in black ink, appearing to read "V.C. Nannapaneni".

V.C. Nannapaneni
Chairman and Managing Director

Hyderabad
7 August 2017



NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034
Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2017

(₹ in millions except per share data)

	Quarter ended			Year ended
	30 June 2017 (Unaudited) (Refer note 4)	31 March 2017 (Refer note 3)	30 June 2016 (Unaudited) (Refer note 4)	31 March 2017 (Audited)
Revenue				
Revenue from operations	4,308	5,553	3,246	20,028
Other income	27	(8)	48	132
Total revenues	4,335	5,545	3,294	20,160
Expenses				
Cost of materials consumed	1,286	1,010	1,308	5,208
Excise duty	172	131	151	448
Purchases of stock-in-trade	187	7	93	687
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(447)	106	(597)	(167)
Employee benefits expenses	603	757	495	2,321
Finance costs	38	59	30	175
Depreciation and amortisation expense	148	132	130	536
Other expenses	1,101	1,129	989	4,611
Total expenses	3,088	3,331	2,599	13,819
Profit before tax	1,247	2,214	695	6,341
Tax expense				
Current tax	266	477	167	1,353
Deferred tax	7	(58)	0	-
Tax for earlier years	-	22	19	40
Profit after tax	974	1,773	509	4,948
Other comprehensive income (net of taxes)				
Items that will not be reclassified to profit or loss				
Re-measurement gains/(losses) on defined benefit plans	(8)	(27)	(8)	(50)
Net gain/(loss) on FVTOCI equity securities	6	19	2	28
Total comprehensive income	972	1,765	503	4,926
Paid-up equity share capital of ₹2 each	349	349	349	349
Other equity				16,648
Earnings per share (non-annualised)				
Basic	5.58	10.13	2.92	28.27
Diluted	5.56	10.11	2.91	28.24



NATCO Pharma Limited

Notes to the standalone results:

1. The Company adopted Indian Accounting Standard ("Ind AS") from 1 April 2016 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.
2. The standalone financial results for the quarter ended 30 June 2017 have been reviewed by the Audit Committee of the board and approved by the Board of Directors of the Company at their meeting held on 7 August 2017.
3. The figures of the quarter ended 31 March 2017 are the balancing figures between audited figures in respect of full financial year ended 31 March 2017 and the unaudited published year to date figures upto 31 December 2016 which were subjected to limited review.
4. The results for the quarter ended 30 June 2017 and 30 June 2016 presented were subjected to a limited review by the statutory auditors of the Company.
5. The Company operates in one reportable segment which is "Pharmaceuticals".
6. The Board of Directors at their meeting held on 7 August 2017 have recommended an interim dividend of ₹1.25 per equity share of ₹2 each for the current financial year.

Hyderabad
7 August 2017

By Order of the Board

A handwritten signature in black ink, appearing to read "V.C. Nannapaneni".

V.C. Nannapaneni
Chairman and Managing Director